ImaginAb inks deal with pharma developer in China

By staff writers

May 25, 2022 -- Immuno-PET developer ImaginAb has signed an exclusive license with DongCheng Pharmaceutical Group to commercialize cancer imaging radiotracers across China.

ImaginAb's radiotracer candidate zirconium-89-labeled minibody (Zr-89 Df-Crefmirlimab) aims to bind to human CD8 T-cell receptors for quantitative PET imaging of tumors in cancer patients. Initially, it will be used in third-party clinical trials, with the goal of obtaining market authorization in the country.

Under the terms of the license, ImaginAb will receive a license fee and be entitled to receive potential milestone payments and double-digit royalties on its CD8 immuno-PET product. No other details were disclosed.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking